|Videos|November 12, 2017

Fecal Microbiota Transplantation: A Brief History

Sahil Khanna, MBBS, MS, provides a brief overview of the history of fecal microbiota transplantation.

Sahill Khanna, MBBS, MS, associate professor of medicine, in the department of Gastroenterology at the Mayo Clinic in Rochester, MN, provides a brief overview of the history of fecal microbiota transplantation.

Interview Transcript (modified slightly for readability):

"Fecal transplant or stool transplant—harnessing bacteria from stool from one living being and putting them into another—has been a practice that’s been around for awhile. If you go back through the history of medicine, as early as the 4th century there were reports in Chinese medicine where they were doing these procedures. There have also been reports in veterinary medicine in the 17th century that this was happening to treat horses with diarrhea.

In modern medicine, the first reports were in 1958, where a surgeon used stool from one person and placed them into another person with Pseudomembranous colitis. At that time, we didn’t even know that C. difficile existed as a cause of human diarrhea. In the late eighties, and now, for the last ten years or so, we’ve seen an upsurge of fecal transplantation being used as a treatment for C. difficile infection clinically, and also being used as research for other diseases.


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
LMN-201 Reduces C difficile Recurrence
In the phase 2 RePreve trial, Lumen Bioscience’s investigational oral biologic LMN-201 plus standard antibiotics achieved global cure in 83.3% of patients with C difficile infection vs 36.4% with placebo, and cut recurrence sixfold (9.1% vs 55.6%) with no drug-related serious adverse events.